TORONTO, ONTARIO–(Marketwired – Jan. 16, 2015) – Arch Biopartners Inc (“Arch”) (CSE:ACH)(OTCBB:FOIFF) has received conditional approval from the TSX Venture Exchange (“TSXV”) for the listing of its common shares on the TSXV.
Final approval is subject to Arch complying with certain TSXV listing conditions by February 7, 2015.
Upon receiving final approval to list its common shares on the TSXV, Arch will issue another press release specifying the last day of trading on the CSE and first day of trading on the TSXV. The trading symbol will remain “ACH”.
Euro Pacific Canada (“EPC”) has been engaged to act as sponsor and prepare a sponsorship report in conjunction with the TSXV listing application. As part of the consideration for acting as sponsor, Arch has agreed to issue 71,500 common shares to EPC, to be held in escrow for one year from the date of issue. The date of issue is expected to be within ten days of the delivery of the sponsorship report to the TSXV.
EPC is a full-service IIROC registered investment dealer headquartered in Toronto with offices in Montreal, Vancouver, and Tokyo, Japan. EPC offers an integrated platform of investment advice and opportunities including economic and equity research, institutional sales and trading, investment banking, and private client services.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for unmet medical needs. The Company’s lead technology is MetaMx. Arch intends to perform a human trial to characterize the safety and pharmacokinetics of MetaMx and to demonstrate the efficacy of MetaMx to cross the human blood brain barrier and detect BTICs and invasive glioma cells. Such results in human patients will increase the value of MetaMx not only as a diagnostic and imaging tool but also as a potential drug delivery platform to destroy BTICs and invasive glioma cells.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com. The Company’s website address is: www.archbiopartners.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.
The CSE has not reviewed and does not accept responsibility for the adequacy of this release.